Targeting cardiovascular medication adherence interventions

Journal of the American Pharmacists Association

Volumn 52, Issue 3, 2012, Pages 381-397

  Cutrona, Sarah L ^a   Choudhry, Niteesh K ^b   Fischer, Michael A ^b   Servi, Amber D ^b   Stedman, Margaret ^b   Liberman, Joshua N ^c   Brennan, Troyen A ^c   Shrank, William H ^b,d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CVS Caremark   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Diabetes; Medication adherence

Indexed keywords

ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LIBENZAPRIL; METFORMIN; METHYLPHENIDATE; METOPROLOL; SIMVASTATIN; TELMISARTAN; CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; COST; DIABETES MELLITUS; DRUG TARGETING; DYSLIPIDEMIA; EFFECT SIZE; ELECTRONIC MEDICAL RECORD; EMBASE; FEEDBACK SYSTEM; FOLLOW UP; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MEDICAL ASSISTANT; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; REVIEW; SELF CONCEPT; SELF REPORT; META ANALYSIS; STATISTICAL ANALYSIS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DATA INTERPRETATION, STATISTICAL; HUMANS; MEDICATION ADHERENCE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866502281     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2012.10211     Document Type: Review

References (68)

1. Institute of Medicine. 100 initial priority topics for comparative effectiveness research. Accessed at www.iom.edu/~/media/Files/Report%20Files/ 2009/ComparativeEffectivenessResearch-Priorities/ Stand%20Alone%20List%20of%20100%20CER%20Priorities%20-%20for%20web.ashx, June 8, 2010.
2. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-86.
3. New England Healthcare Institute. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease. Accessed at www.nehi.net/publications/44/thinking-outside-the-pillbox- a-systemwide-approach-to-improving-patient-medication-adherence-for-chronic- disease, May 27, 2010.
4. Kripalani S, Yao X, Haynes R. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-50.
5. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
6. Cohen J. Statistical power analysis for the behavioral sciences. New York: Lawrence Erlbaum Associates; 1988.
7. Dunlap W, Cortina J, Vaslow J, Burke M. Meta-analysis of experiments with matched groups or repeated measures designs. Psychological Methods. 1996;1:170-7.
8. Hedges L, Olkin I. Statistical methods for meta-analysis. San Diego, CA: Academic Press; 1985.
9. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.
10. Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncontrolled hypertension. Lancet. 1976;1:1265-8.
11. Rosen MI, Rigsby MO, Salahi JT, et al. Electronic monitoring and counseling to improve medication adherence. Behav Res Ther. 2004;42:409-22.
12. Saunders LD, Irwig LM, Gear JS, Ramushu DL. A randomized controlled trial of compliance improving strategies in Soweto hypertensives. Med Care. 1991;29:669-78.
13. Taylor CT, Byrd DC, Krueger K. Improving primary care in rural Alabama with a pharmacy initiative. Am J Health Syst Pharm. 2003;60:1123-9.
14. Avanzini F, Corsetti A, Maglione T, et al. Simple, shared guidelines raise the quality of antihypertensive treatment in routine care. Am Heart J. 2002;144:726-32.
15. Birtwhistle RV, Godwin MS, Delva MD, et al. Randomised equivalence trial comparing three and six months of follow up of patients with hypertension by family practitioners. BMJ. 2004;328:204.
16. Christensen A, Christrupa LL, Fabriciusb PE, et al. The impact of an electronic monitoring and reminder device on patient compliance with antihypertensive therapy: a randomized controlled trial. J Hypertens. 2010;28:194-200.
17. Dusing R, Handrock R, Klebs S, et al. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE. J Hypertens. 2009;27:894-901.
18. Emmett CL, Montgomery AA, Peters TJ, Fahey T. Three-year follow-up of a factorial randomised controlled trial of two decision aids for newly diagnosed hypertensive patients. Br J Gen Pract. 2005;55:551-3.
19. Hamet P, Campbell N, Curnew G, et al. Avapromise: a randomized clinical trial for increasing adherence through behavioural modification in essential hypertension. Exp Clin Cardiol. 2003;7:165-72.
20. Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm. 1979;36:1321-5.
21. Johnson AL, Taylor DW, Sackett DL, et al. Self-recording of blood pressure in the management of hypertension. Can Med Assoc J. 1978;119:1034-9.
22. Kirscht JP, Kirscht JL, Rosenstock IM. A test of interventions to increase adherence to hypertensive medical regimens. Health Education Quarterly. 1981;8:261-72.
23. Logan AG, Milne BJ, Achber C, et al. Work-site treatment of hypertension by specially trained nurses: controlled trial. Lancet. 1979;2:1175-8.
24. Lopez Cabezas C, Falces Salvador C, Cubi Quadrada D, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure. Farm Hosp. 2006;30:328-42.
25. Mann DM, Ponieman D, Montori VM, et al. The statin choice decision aid in primary care: a randomized trial. Patient Educ Couns. 2010;80:138-40.
26. Marquez-Contreras E, Martell-Claros N, Gil-Guillen V, et al. Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. J Hypertens. 2006;24:169-75.
27. Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy. 2000;20:1384-9.
28. Morisky DE, DeMuth NM, Field-Fass M, et al. Evaluation of family health education to build social support for long-term control of high blood pressure. Health Educ Q. 1985;12:35-50.
29. Mullan RJ, Montori VM, Shah ND, et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med. 2009;169:1560-8.
30. Powell KM, Edgren B. Failure of educational videotapes to improve medication compliance in a health maintenance organization. Am J Health Syst Pharm. 1995;52:2196-9.
31. Rudd P, Miller NH, Kaufman J, et al. Nurse management for hypertension: a systems approach. Am J Hypertens. 2004;17:921-7.
32. Sackett DL, Gibson ES, Taylor DW, et al. Randomized clinical trial of strategies for improving medication compliance in primary hypertension. Lancet. 1975;1:1205-7.
33. Sclar DA, Chin A, Skaer TL, et al. Effect of health-education in promoting prescription refill compliance among patients with hypertension. Clin Ther. 1991;13:489-95.
34. Smith DH, Kramer JM, Perrin N, et al. A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. Arch Intern Med. 2008;168:477-83.
35. Stewart A, Noakes T, Eales C, et al. Adherence to cardiovascular risk factor modification in patients with hypertension. Cardiovasc J S Afr. 2005;16:102-7.
36. Takala J. Screening, treatment and adherence to treatment for hypertension. Scand J Prim Health Care. 1983;1:114-9.
37. van Onzenoort HA, Verberk WJ, Kroon AA, et al. Effect of self-measurement of blood pressure on adherence to treatment in patients with mild-to-moderate hypertension. J Hypertens. 2010;28:622-7.
38. Yilmaz MB, Pinar M, Naharci I, et al. Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther. 2005;19:437-40.
39. Antonicelli R, Testarmata P, Spazzafumo L, et al. Impact of telemonitoring at home on the management of elderly patients with congestive heart failure. J Telemed Telecare. 2008;14:300-5.
40. Blenkinsopp A, Phelan M, Bourne J, Dakhil N. Extended adherence support by community pharmacists for patients with hypertension: a randomised controlled trial. Int J Pharm Pract. 2000;8:165-75.
41. Bouvy ML, Heerdink ER, Urquhart J, et al. Effect of a pharmacistled intervention on diuretic compliance in heart failure patients: a randomized controlled study. J Card Fail. 2003;9:404-11.
42. Edworthy SM, Baptie B, Galvin D, et al. Effects of an enhanced secondary prevention program for patients with heart disease: a prospective randomized trial. Can J Cardiol. 2007;23:1066-72.
43. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy. 2000;20:410-6.
44. Friedman RH, Kazis LE, Jette A, et al. A telecommunications system for monitoring and counseling patients with hypertension: impact on medication adherence and blood pressure control. Am J Hypertens. 1996;9:285-92.
45. Guthrie RM. The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the First Myocardial Infarction Risk Reduction Program. Clin Ther. 2001;23:970-80.
46. Hunt JS, Siemienczuk J, Pape G, et al. A randomized controlled trial of team-based care: impact of physician-pharmacist collaboration on uncontrolled hypertension. J Gen Intern Med. 2008;23:1966-72.
47. Jaffray M, Bond C, Watson M, et al. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Fam Pract. 2007;24:189-200.
48. Krantz MJ, Havranek EP, Haynes DK, et al. Inpatient initiation of beta-blockade plus nurse management in vulnerable heart failure patients: a randomized study. J Card Fail. 2008;14:303-9.
49. Logan AG, Milne BJ, Flanagan PT, Haynes RB. Clinical effectiveness and cost-effectiveness of monitoring blood-pressure of hypertensive employees at work. Hypertension. 1983;5:828-36.
50. Odegard PS, Goo A, Hummel J, et al. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother. 2005;39:433-40.
51. Ogedegbe G, Chaplin W, Schoenthaler A, et al. A practice-based trial of motivational interviewing and adherence in hypertensive African Americans. Am J Hypertens. 2008;21:1137-43.
52. Piette JD, Weinberger M, McPhee SJ, et al. Do automated calls with nurse follow-up improve self-care and glycemic control among vulnerable patients with diabetes? Am J Med. 2000;108:20-7.
53. Planas LG, Crosby KM, Mitchell KD, Farmer KC. Evaluation of a hypertension medication therapy management program in patients with diabetes. J Am Pharm Assoc. 2009;49:164-70.
54. Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with heart failure. Br J Clin Pharmacol. 2005;60:183-93.
55. Schectman G, Hiatt J, Hartz A. Telephone contacts do not improve adherence to niacin or bile-acid sequestrant therapy. Ann Pharmacother. 1994;28:29-35.
56. Schroeder K, Fahey T, Hollinghurst S, Peters TJ. Nurse-led adherence support in hypertension: a randomized controlled trial. Fam Pract. 2005;22:144-51.
57. Solomon DK, Portner TS, Bass GE, et al. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc. 1998;38:574-85.
58. Sookaneknun P, Richards RM, Sanguansermsri J, Teerasut C. Pharmacist involvement in primary care improves hypertensive patient clinical outcomes. Ann Pharmacother. 2004;38:2023-8.
59. Stacy JN, Schwartz SM, Ershoff D, Shreve MS. Incorporating tailored interactive patient solutions using interactive voice response technology to improve statin adherence: results of a randomized clinical trial in a managed care setting. Popul Health Manag. 2009;12:241-54.
60. Tsuyuki RT, Fradette M, Johnson JA, et al. A multicenter disease management program for hospitalized patients with heart failure. J Card Fail. 2004;10:473-80.
61. Varma S, McElnay JC, Hughes CM, et al. Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. Pharmacotherapy. 1999;19:860-9.
62. Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy. 2002;22:1533-40.
63. Johnson SS, Driskell MM, Johnson JL, et al. Transtheoretical model intervention for adherence to lipid-lowering drugs. Dis Manag. 2006;9:102-14.
64. Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med. 2007;146:714-25.
65. Phumipamorn S, Pongwecharak J, Soorapan S, Pattharachayakul S. Effects of the pharmacist's input on glycaemic control and cardiovascular risks in Muslim diabetes. Prim Care Diabetes. 2008;2:31-7.
66. Robinson JD, Segal R, Lopez LM, Doty RE. Impact of a pharmaceutical care intervention on blood pressure control in a chain pharmacy practice. Ann Pharmacother. 2010;44:88-96.
67. Tamblyn R, Reidel K, Huang A, et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Med Decis Making. 2010;30:176-88.
68. Vrijens B, Belmans A, Matthys K, et al. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf. 2006;15:115-21.